An interventional study of Maximal strenght training (MST) plus endurance training (ET) and Endurance training (ET) in Chronic Obstructive Pulmonary Disease, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 1 site in Italy. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Istituti Clinici Scientifici Maugeri SpA.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 11 with no phase, and was the 2nd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →5 of the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA are open now, in 1 country. Recruiting first, the newest first:
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 40–85
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 20 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 50 across the 11 interventional studies, 101 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720780Istituti Clinici Scientifici Maugeri SpARehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients. | 2026-12-31 |
| NCT03799354Istituti Clinici Scientifici Maugeri SpAStudy on Impact of Maximal Strength Training in Patients With COPD | 2027-02-28 |
| NCT05708443Istituti Clinici Scientifici Maugeri SpAEffect of Combined Endurance Training on ADL and Walking in COPD Patients | 2027-02-28 |
| NCT07302425Istituti Clinici Scientifici Maugeri SpAHigh-intensity Resistance Training in Post-exacerbation COPD | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of adverse events.
Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase. Recent literature indicates a significant amelioration on the Rate of Force Development (RFD) after MST in healthy subjects, post-menopausal woman and older populations.
When comparing to the conventional ET, MST generates a little change in muscle mass (no hypertrophy), but a much greater improvement in the RFD. It has been described that neural adjustments play a major role in the MST-induced adaptations. MST is also well documented to improve aerobic endurance by improving walking work efficiency.
Only a small cohort study of COPD patients was conducted, describing that MST can meaningfully improve strength and RFD, with an increase of around 32% for mechanical efficiency and a decrease of the perceived effort during submaximal job. This improvement could determine best performances in daily activities and a best quality of life. The main aims of this physiological pilot randomized controlled trail will be to evaluate feasibility and efficacy of the MST compared to standard ET on strength, effort tolerance, fatigue, economy of walking, dyspnea and risk of falls in a populations of COPD patients, in a short and middle term (6 months).
Exercise intolerance is a cardinal problem existing in patients with Chronic Obstructive Pulmonary Disease (COPD). Moreover, skeletal muscle dysfunction is a common extra-pulmonary manifestation, leading to fatigue, decrease in activity of daily living (ADL) performance and quality of life and increase of risk of falls, mainly in older patients. In the context of pulmonary rehabilitation, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of adverse events.
As concern the RT programs, metanalysis in COPD describe that training have been mainly performed with the lower limbs and the training intensities are heterogeneous, generally ranging from 40% to 70% of 1-Repetition Maximum (1-RM).
Maximal Strength Training (MST) is a RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase. Recent literature indicates a significant amelioration on the Rate of Force Development (RFD) after MST in healthy subjects, post-menopausal woman and older populations.
When comparing to the conventional ET, MST generates a little change in muscle mass (no hypertrophy), but a much greater improvement in the RFD. It has been described that neural adjustments play a major role in the MST-induced adaptations. MST is also well documented to improve aerobic endurance by improving walking work efficiency.
Although the mechanisms at the base of MST effect on the mechanical efficiency have not been completely clarified, there is evidence that changes in the relationships between power and speed bring to a longer relaxation phase inside the cycle of job, improving the recovery between contractions.
In this field, only a small cohort study of COPD patients was conducted describing that MST can meaningfully improve the strength and the RFD, with an increase of around 32% for mechanical efficiency and a decrease of the perceived effort during submaximal job. This improvement could determine best performances in daily activities and a best quality of life. Nevertheless, this study has been conducted only in a small cohort (twelve patients) of patients with COPD and further studies are necessary to define the impact on the different components that determine the effort intolerance.
The main aim of this physiological pilot randomized controlled trail will be to test the feasibility and the efficacy of the MST compared to standard ET on strength, effort tolerance, fatigue, economy of walking, dyspnea and risk of falls in a populations of COPD patients, in a short and middle term (6 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maximal strenght training (MST) plus endurance training (ET)
Other: Maximal strenght training (MST) plus endurance training (ET)
Endurance training (ET)
Other: Endurance training (ET)
Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of: 1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press. 2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression.
Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session. Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician.
Change in walking efficiency
The text will be executed using a portable metabolimeter detecting oxygen consumption (VO2). After a 10 min of warm up on a treadmill, the patient will walk 5 min at submaximal steady state walking at 4.5 km/h at 5% incline. Using the average of VO2 of the last minute of walking, the walking efficiency will be defined as percentage of change as follows: external work accomplished/ energy expenditure x 100.
Time frame: baseline and 8 weeks
Change in Leg Strength by 1-Repetition Maximum on leg press
1-Repetition Maximum (1RM) will be evaluated. 1RM will be measured on a horizontal leg press at a knee angle of 90°. 1RM will be recorded as the heaviest lifted load achieved, applying rest periods of \~4 min between test lifts and increments of 5 kg between each trial until failure.
Time frame: baseline and 8 weeks
Change in maximal Rate of Force Development (RFD)
Immediately after the maximal test 1-RM (see above), using the same apparatus, maximal rate of Force Development (RFD) will be assessed using a force platform and applying a load corresponding to 75% of the participant's pre-test 1RM. The subjects will be instructed to execute the lift as rapidly as possible in the concentric phase. RFD will be analyzed as the time difference between 10% and 90% of Peak force.
Time frame: baseline and 8 weeks
Change in maximal effort tolerance
It will be evaluated by VO2 consumption on maximal cardiopulmonary exercise test (CPET) on cycloergometer
Time frame: baseline and 8 weeks
Change in Constant Load Effort tolerance
It will be evaluated by evaluated by time of execution of Cardiopulmonary Constant-Load Endurance Test
Time frame: baseline and 8 weeks
Change in Fatigue (physiological evaluation)
To define peripheral and central component of fatigue, before and after CLET, the investigators will test the difference on force produced during a single twitch superimposed on the Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
Time frame: baseline and 8 weeks
Change in Fatigue (qualitative evaluation)
Fatigue Severity Scale (scale measuring fatigue, 9-item scale ranging from 7 = absence of fatigue to 63= maximal presence of fatigue)
Time frame: baseline and 8 weeks
Change in Muscle volume
Sagittal ultrasound images of the Vastus Lateralis (VL) muscle will be recorded with an 8-12 MHz linear transducer. Images will be obtained with a 90° flexion of hip and knee, at 50% of femur length. The pennation angle (hp) of the VL fascicles will be measured as the angle between the VL muscle fascicles and the deep aponeurosis of the insertion.
Time frame: baseline and 8 weeks
Change in Dyspnea
Barthel Index Dyspnea (scale measuring dyspnea during basal ADL, 10-item scale ranging from 0 = absence of dyspnea to 100 = maximal dyspnea)
Time frame: baseline and 8 weeks
Concentration of CRP
C reactive protein \[CRP\] (mg/dl)
Time frame: baseline and 8 weeks
Change in Low grade Inflammation
Evaluation of neutrophils/ lymphocytes ratio
Time frame: baseline and 8 weeks
Concentration of Tumor necrosis factor alpha
TNF-alpha (pg/ml)
Time frame: baseline and 8 weeks
Concentration of Interleukin-6
IL6 (pg/ml)
Time frame: baseline and 8 weeks
Muscular proteolyses by 3-MeH concentration
Evaluation of urinary 3 Methyl-Histine (3-MeH) (micromol/ml)
Time frame: baseline and 8 weeks
Change in Balance (qualitative measure)
BERG scale ( scale measuring balance, composed by 14 balance related tasks, ranging from 0 = worse balance to 56= best balance)
Time frame: baseline and 8 weeks
Change in quality of life
EuroQol 5-D (scale measuring quality of life, composed by 2 sessions: one of 5 questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with multiple choice ranging from 0 = no problem to 25= very low quality of life and one using Visual Analogic Scale (VAS) to quantify the health status ranging from 0 = worst health condition to 100 = best health condition. The two scale sessions are considered separately.
Time frame: baseline and 8 weeks
Patient Satisfaction: Likert Scale
Likert Scale 0-4 ( 0=completely unsatisfied, 4= very satisfied).
Time frame: at 8 weeks
Change in Falls
Evaluation of the rate of falls
Time frame: baseline and 8 months
Hospitalizations
Evaluation of the rate of hospitalizations
Time frame: baseline and 8 months
Mortality
Evaluation of deaths (number)
Time frame: baseline and 8 months
Change in Balance (quantitative measure)
The fall risk (FR) assessment will be evaluated by Balance Board.
Time frame: baseline and 8 weeks
Plan to share: No
Started Sep 2019 (actual). Primary completion is estimated for Feb 2027, 89 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 89 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion May 2026 → Feb 2027 and completion Jul 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Istituti Clinici Scientifici Maugeri SpA →